Vice President and Medical Director Clinical Pharmacology of Miami, Inc.
Cardiology
Dr. Kenneth C. Lasseter, MD
|
|
Give Review
Kenneth Lasseter practices Cardiology. He went to University of Kentucky College of Medicine. University of Kentucky College of Medicine has a rank of 63 in research and a 72 in primary care Kenneth C. Lasseter is a published doctor as well. He has 101 publications published. The latest was: Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
Publications
- Influence of Renal and Hepatic Impairment on the Pharmacokinetics of Anacetrapib.
- Evaluation of the Single-dose Pharmacokinetics of Bilastine in Subjects with Various Degrees of Renal Insufficiency.
- Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies...
- An Open-Label Investigation of the Pharmacokinetic Profiles of Lisdexamfetamine Dimesylate and Venlafaxine Extended-Release, Administered Alone and in Combination, in ...
- Safety and pharmacokinetics of multiple doses of aclidinium bromide administered twice daily in healthy volunteers.
- Aclidinium Bromide, a Long-Acting Antimuscarinic, Does Not Affect QT Interval in Healthy Subjects.
- Pharmacokinetics of Oral Tonapofylline and Its Acyl-Glucuronide Metabolite in Patients With Mild and Moderate Hepatic Impairment.
- Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment.
- Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Does Not Affect the Pharmacokinetics of Ethinyl Estradiol or Norethindrone in Healthy Female Subjects.
- Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.
- Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
- Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
- Ketoconazole increases fingolimod blood levels in a drug interaction via CYP4F2 inhibition.
- Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharm...
- Influence of taranabant, a cannabinoid-1 receptor inverse agonist, on pharmacokinetics and pharmacodynamics of warfarin.
- Lack of a significant drug interaction between raltegravir and tenofovir.
- Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension.
- Ghrelin agonist (TZP-101): safety, pharmacokinetics and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.
- Effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs on urinary sodium excretion, blood pressure, and other renal function indicators in elderly s...
- Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
- Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
- Intravenous conivaptan: effects on the QTc interval and other electrocardiographic parameters in healthy volunteers.
- Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients ...
- Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
- Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
- Pharmacokinetics of sirolimus (rapamycin) in subjects with mild to moderate hepatic impairment.
- Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
- Potential for interactions between caspofungin and nelfinavir or rifampin.
- Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.
- The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
- Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
- Pharmacokinetics of etoricoxib in patients with hepatic impairment.
- Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers.
- Single- and multiple-dose pharmacokinetics of etoricoxib, a selective inhibitor of cyclooxygenase-2, in man.
- Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers.
- Pharmacokinetic and safety assessments of galantamine and risperidone after the two drugs are administered alone and together.
- Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.
- The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects.
- Effect of rosuvastatin on warfarin pharmacodynamics and pharmacokinetics.
- Asenapine pharmacokinetics in hepatic and renal impairment.
- Absorption, metabolism, and excretion of [14C]MK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) in humans.
- Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects.
- Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme.
- Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
- Dose-proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers.
- Effect of a single cyclosporine dose on the single-dose pharmacokinetics of sitagliptin (MK-0431), a dipeptidyl peptidase-4 inhibitor, in healthy male subjects.
- Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans.
- Effect of moderate hepatic insufficiency on the pharmacokinetics of sitagliptin.
- Pharmacokinetic evaluation of rofecoxib : comparison of tablet and suspension formulations.
- Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
- Single-dose pharmacokinetics and pharmacodynamics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
- Pharmacokinetic considerations in determining the terminal elimination half-lives of bisphosphonates.
- The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin.
- Bioequivalence of an ezetimibe/simvastatin combination tablet and coadministration of ezetimibe and simvastatin as separate tablets in healthy subjects.
- Pharmacokinetics and pharmacodynamics of rosuvastatin in subjects with hepatic impairment.
- Pharmacokinetics and safety of ebastine in patients with impaired hepatic function compared with healthy volunteers: a phase I open-label study.
- FTY720 pharmacokinetics in mild to moderate hepatic impairment.
- Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet.
- The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
- Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids.
- Effective dose range of candesartan cilexetil for systemic hypertension. Candesartan Cilexetil Study Investigators.
- Pharmacokinetics and pharmacodynamics of zolmitriptan in patients with mild to moderate hypertension: a double-blind, placebo-controlled study.
- First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.
- Pharmacokinetics and pharmacodynamics of irbesartan in patients with hepatic cirrhosis.
- Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans.
- Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile.
- Evaluation of indapamide 1.25 mg once daily in elderly patients with mild to moderate hypertension.
- Interactions between simvastatin and troglitazone or pioglitazone in healthy subjects.
- Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin.
- Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.
- Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
- Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients.
- Once- and twice-daily nitrendipine in patients with hypertension and noninsulin-dependent diabetes.
- The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin.
- Pharmacokinetics and bioavailability of Sinemet CR: a summary of human studies.
- Effect of MK-906, a specific 5 alpha-reductase inhibitor, on serum androgens and androgen conjugates in normal men.
- Profile of etodolac: pharmacokinetic evaluation in special populations.
- Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril hydrochloride.
- Effects of finasteride (MK-906), a 5 alpha-reductase inhibitor, on circulating androgens in male volunteers.
- The disposition of [14C]-labelled benazepril HCl in normal adult volunteers after single and repeated oral dose.
- The effects of benazepril, a new angiotensin-converting enzyme inhibitor, in mild to moderate essential hypertension: a multicenter study.
- Comparative absorption of atropine from a metered-dose inhaler and an intramuscular injection.
- Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin.
- Epoetin enhances erythropoiesis in normal men undergoing repeated phlebotomies.
- Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension.
- Letter: Nitroprusside and aortic dissecting aneurysm.
- Drug therapy. Sodium nitroprusside.
- Automated on-line determination of membrane responsiveness curves.
- Piperacillin kinetics.
- Nefopam HCl interaction study with eight other drugs.
- Steady-state pharmacokinetics of nitrendipine in hepatic insufficiency.
- Pharmacokinetics of guanabenz in patients with impaired liver function.
- A mechanism for "false" inhibition of demand pacemakers.
- Electrocardiogram in pericarditis.
- Treatment of arrhythmias: basic considerations.
- Dissecting aneurysm of the aorta as an unusual cause of "asthma"--an anatomicopharmacologic correlation.
- Sulfonylureas and the heart.
- The effect of sulfonylurea drugs on rabbit myocardial contractility, canine purkinje fiber automaticity, and adenyl cyclase activity from rabbit and human hearts.
- Effect of tolbutamide on adenyl cyclase in rabbit and human heart and contractility of isolated rabbit atria.
- Stimulation of Na+ and K+ dependent adenosine triphosphatase by ouabain.
Schools
University Of Florida
Doctors Specialties
- Cardiology
Accepted Insurances
Education
-
University of Kentucky College of Medicine -
University of Florida College of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Ricardo L. Machado, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manuel Bouza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pedro O. Diaz, MD |
|
Dr. Raul Alonso, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Esteban Escolar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gilbert Concepcion, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alvaro I. Martinez Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Ariel De La Rosa, MD |
|
Dr. Alvaro I. Martinez Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jaime J. Sanchez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio C. Cano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Marcos A. Junges, ARNP |
|
|
Dr. Guillermo Pena, MD
This Doctor is OpenDoctor Recommended.
|